Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04511780
Other study ID # Local/2020/JYL-03
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 2021
Est. completion date September 2022

Study information

Verified date December 2020
Source Centre Hospitalier Universitaire de Nimes
Contact Jean Yves LEFRANT
Phone +33466683331
Email jean.yves.lefrant@chu-nimes.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Based on the experience of previous pandemics, countries reacted by applying different upgrade strategies to prevent or delay the widespread of the disease. Therefore, measures such as border closure, school closure, restrict social gathering (even shutdown of workplaces), limit population movements, and confinement meaning quarantines at the scale of cities or regions. In public hospitals, several measures have been decided to concentrate the power of care on potential wave of admissions of patients with severe forms of Covid-19. In this purpose, the number of available beds in Intensive Care Units (ICU) has been increased by two-fold and scheduled non-emergency surgical procedure have been cancelled. That means: 1. For the most severe patients, new personals (physician such as anesthesiologists, nurses of other units) have been transferred in ICUs. 2. For the less severe patients, personals of non-busy units have been transferred in busier ones. All these measures lead to major daily-life change sets that could be stressful. In the general population, it has been well documented that quarantine or confinement or isolation could lead to the occurrence of Post-Traumatic Stress Disorder (PTSD) syndrome in about 30% overall population. Importantly, high depressive symptoms have been reported in 9% of hospital staff. Numerous symptoms have been reported after quarantine or isolation such as emotional disturbance, depression, stress, low mood, irritability, insomnia, and post-traumatic stress symptoms. In hospital setting, few studies have been performed for assessing the psychological impact of quarantine and isolation. However, two studies reported a high prevalence of burn-out syndrome (BOS) in ICU physician and PTSD syndrome and depression in ICU nurses. As the consequences of all the measures decided and applied during Covid-19 pandemic could be important on caregivers, the present study primarily aims at assessing the prevalence of PTSD syndrome in a large population of caregivers implied or not in Intensive Care Units. The secondary objective were 1) to assess the prevalence of severe depression and anxiety and BOS 2) to isolate potential factors associated with PTSD, severe depression, anxiety or BOS.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 5000
Est. completion date September 2022
Est. primary completion date September 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Caregivers (doctors senior and junior, nurses, aid nurses) involved in the staff (permanent or transient, full or partial time) of ICU patients during Covid-19 outbreak - Approved to participate Exclusion Criteria: - Participation refusal - No internet connection for responding to the questionnaire with REDCAP file

Study Design


Intervention

Other:
questionnaire filling
assessment of post-traumatic stress, anxiety and burn out

Locations

Country Name City State
France Intensive Care Unit, CHU d'Amiens Amiens
France Intensive Care Unit, CHU d'Angers Angers
France CHU de Besançon Besançon
France CHU de Bordeaux, Hôpital Pellegrin Bordeaux
France Intensive care Unit CHU de Brest Hôpital Cavale Blanche Brest
France CHU de Caen Caen
France CHU de Clermont Ferrand Clermont-Ferrand
France AP-HP, Hôpital Henri Mondor Créteil
France CHU de dijon Dijon
France CHU de Grenoble, Hôpital Michalon La Tronche
France AP_HP, Hôpital du Kremlin Bicêtre Le Kremlin-Bicêtre
France Intensive Care Unit, CHRU de Lille Lille
France Intensive Care Unit, CHU de Limoges Limoges
France Hôpitaux civils de Lyon, Hôpital de la Croix Rousse Lyon
France Hôpitaux civils de Lyon, Hôpital Edouard Herriot Lyon
France Hôpitaux civils de Lyon, Hôpital Louis Pradel Lyon
France AP-HM, Hôpital e la Conception Marseille
France AP-HM, Hôpital Nord Marseille
France AP-HM, Hôpital Timone adultes, Intensive Care Unit Marseille
France AP-HM, Hôpital Timone adultes, Neurotraumatology Marseille
France CHU de Montpellier, Hôpital Guy de chauliac Montpellier
France CHU de Montpellier, Hôpital Lapeyronie Montpellier
France CHU De Montpellier, Hôpital St Eloi Montpellier
France CHU de Montpellier, Hôpital St Eloi SAR B Montpellier
France CHU De Montpellier, Hôpital St Eloi-DAR B Montpellier
France Intensive Care Unit, CHU de Mulhouse Mulhouse
France Intensive CAre Unit CHRU de Nancy, Hôpital Central Nancy
France Intensive Care Unit, CHU de Nantes Nantes
France Intensive Care Unit, CHU de Nantes, Hôtel Dieu Nantes
France CHU de Nice Nice
France Intensive care Unit CHU Nîmes Nîmes
France AP-HP, Hôpital Bichât Paris
France AP-HP, Hôpital de la Pitié Paris
France AP-HP, Hôpital Lariboisière Paris
France AP-HP, Hôpital St Antoine Paris
France AP_HP, Hôpital G Pompidou Paris
France AP6HP, Hôpital St Loui Paris
France CH de Perpignan Perpignan
France CHU de Bordeaux, Hôpital Haut Leveque Pessac
France Intensive care Unit, Hôpitaux civils de Lyon, Lyon Sud Pierre-Bénite
France CHU de Poitiers Poitiers
France Intensive care Unit CHU de Rennes Rennes
France CHU de Rouen Rouen
France CHU de St Etienne, Hôpital Nord Saint-Étienne
France Intensive Care Unit, CHU de Nantes, Hôpital Laennec Saint-Herblain
France Intesive Care Unit CHRU de Strasbourg, Hôpital civil Strasbourg
France Intesive Care Unit CHRU de Strasbourg, Hôpital Hautepierre Strasbourg
France CHU de Toulouse Toulouse
France Intensive care unit CHU de Tours Tours
France Intensive CAre Unit CHRU de Nancy, Hôpital de Brabois VandÅ“uvre-lès-Nancy
France CH de Vesoul Vesoul

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-Traumatic Stress Disorder PCL - 5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) 3-6 month after the Covid-19 outbreak
Secondary anxiety and depression HADS scale (Hospital Anxiety and Depression Scale) 3-6 month after the Covid-19 outbreak
Secondary Burn out Score MBI (Burn out syndrome) 3-6 month after the Covid-19 outbreak
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3